Amyloid β-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
We previously reported that the precursor form of nerve growth factor (pro-NGF) and not mature NGF is liberated in the CNS in an activity-dependent manner, and that its maturation and degradation occur in the extracellular space by the coordinated action of proteases.Here, we present evidence of diminished conversion of pro-NGF to its mature form and of greater NGF degradation in Alzheimer disease (AD) brain samples compared with controls. These alterations of the NGF metabolic pathway likely resulted in the increased pro-NGF levels. The pro-NGF was largely in a peroxynitrited form in the AD samples. Intrahippocampal injection of amyloid-beta oligomers provoked similar upregulation of pro-NGF in naive rats that was accompanied by evidence of microglial activation (CD40), increased levels of inducible nitric oxide synthase, and increased activity of the NGF-degrading enzyme matrix metalloproteinase 9. The elevated inducible nitric oxide synthase provoked the generation of biologically inactive, peroxynitrite-modified pro-NGF in amyloid-beta oligomer-injected rats. These parameters were corrected by minocycline treatment. Minocycline also diminished altered matrix metalloproteinase 9, inducible nitric oxide synthase, and microglial activation (CD40); improved cognitive behavior; and normalized pro-NGF levels in a transgenic mouse AD model. The effects of amyloid-beta amyloid CNS burden on NGF metabolism may explain the paradoxical upregulation of pro-NGF in AD accompanied by atrophy of forebrain cholinergic neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Neurotrophins and Neuronal Plasticity
Thoenen, H. (1995) · Science · doi:10.1126/science.270.5236.593 · Cited by 1,927
Regulation of Cell Survival by Secreted Proneurotrophins
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001) · Science · doi:10.1126/science.1065057 · Cited by 1,670
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“Activation of microglia by aggregated AA is a central feature in the chronic inflammatory pathology in AD (22) anda direct indicator of an ongoing chronic inflammatory process.”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., & Perry, G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02653.1997 · Cited by 1,239
S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C., & Lipton, S. A. (2002) · Science · doi:10.1126/science.1073634 · Cited by 950
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
Peroxynitrite reactivity with amino acids and proteins
Alvarez, B., & Radi, R. (2003) · Amino Acids · doi:10.1007/s00726-003-0018-8 · Cited by 560 · cited 1×
“Peroxynitrite is a potent oxidant and nitrating agent involved in the oxidation and nitration of tyrosine residues in proteins (47, 52).”
BackgroundNeurodegenerative disorders: the role of peroxynitrite
Torreilles, F., Salman-Tabcheh, S., Guérin, M.-C., & Torreilles, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00014-4 · Cited by 430 · cited 1×
“Peroxynitrite is a potent oxidant and nitrating agent involved in the oxidation and nitration of tyrosine residues in proteins (47, 52).”
BackgroundXie, Z., Wei, M., Morgan, T. E., Fabrizio, P., Han, D., Finch, C. E., & Longo, V. D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03484.2002 · Cited by 272
Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer’s disease.
Lorenzl, S. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00004-4 · Cited by 243
Lüth, H.-J., Holzer, M., Gärtner, U., Staufenbiel, M., & Arendt, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02758-5 · Cited by 183 · cited 1×
“Inducible NOS is found in activated microglia, whereas NO production (23) and neuronal expression of iNOS are also found in AD brains (24, 25).”
BackgroundLee, C. Z., Yao, J. S., Huang, Y., Zhai, W., Liu, W., Guglielmo, B. J., Lin, E., Yang, G.-Y., & Young, W. L. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600268 · Cited by 78 · cited 6×
“To test this, rats infused with soluble AA oligomers were treated with minocycline, a tetracycline derivative that has been shown to attenuate microglial activation by decreasing the production of proinflammatory molecules (35), lowering iNOS expression (36, 37) and inhibiting MMP-9 (12).”
MethodInfluential
Cited by
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
Hampel, H., Mesulam, M.-M., Cuello, A. C., Khachaturian, A. S., Vergallo, A., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.43 · Cited by 369
Self-citationA Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
“Studies in transgenic animal models of AD indicate that the proinflammatory process—initiated before plaque deposition and promoted by soluble Aβ oligomers—leads to an impairment of NGF metabolic pathway characterized by a reduced conversion of the precursor proNGF to the mature NGF (mNGF) as well as by an increased d…”
BackgroundSelf-citationExercise Plays a Preventive Role Against Alzheimer's Disease
Radak, Z., Hart, N., Sarga, L., Koltai, E., Atalay, M., Ohno, H., & Boldogh, I. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091531 · Cited by 316
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Metadata
- Authors
- Bruno, M. A., Leon, W. C., Fragoso, G., Mushynski, W. E., Almazan, G., & Cuello, A. C.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08
- Volume
- 68
- Issue
- 8
- Pages
- 857-869
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W2036780475
- Cited by
- 149
- References
- 17
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.